



Health for Life Capital™ participates in \$35m Series B of of Foodscience *MycoTechnology Inc* and confirms its visionary strategy

-Health for Life Capital™ is the only non-American investor alongside prestigious strategic and financial investors

-This financing illustrates growing interest of investors in alternative naturalFood Science

-Funds to be used to commercialize and manufacture Mycotechnology sustainable non-GMO vegan mushroom protein

Paris, France – 18 September 2017 – Seventure Partners, one of Europe’s leaders in innovation financing, and a world-leader in the venture investment in the microbiome sector, today announces that, through its *Health for Life Capital™* investment vehicle, it has participated in a US\$35m financing of MycoTechnology, a company harnessing nature to develop unique innovative ingredients to solve some of the toughest challenges in the food and beverage industry.

Founded in 2013 in Colorado, US, MycoTechnology utilizes a proprietary mushroom-based food-processing platform to transform the flavour of agricultural products. The platform is used to provide the food and beverage industry with innovative solutions, such as its ClearTaste™, an organic flavour modifier used to improve flavour profiles and block bitterness in food. Recently, Mycotechnology announced the launch of Puretaste™, its vegan mushroom protein. Unlike some other novel proteins manufactured in tanks via a fermentation process, Puretaste™, a slightly nutty-tasting spray dried powder containing 77-80% protein by dry weight, does not use GMO yeast or other microorganisms, but uses naturally occurring mycelium (the filament-like roots) from shitake mushrooms that convert feedstock into high quality complete vegan protein.

In 2015, *Health for Life Capital™*, co-led a 8M\$ Series A with American investors.

Health for Life Capital™, now participates to the 35M\$ series B with Kellogg Ventures, Bunge Ventures, S2G and Emerson Collective.

Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, said: *“Finding innovative and healthy ways to increase global food supply, whilst managing the environment is a major challenge. MycoTechnology’s approach could revolutionize the food and beverage industry, providing manufacturers with environmentally-friendly and cost-effective ingredients to help them drive innovation. The market is responding well to organic ingredients such as MycoTechnology’s and it is*

thus an attractive candidate for investment through Health for Life Capital™, bringing together Food Science and innovation.”

“Bringing together strategic and financial investors around breakthrough innovations is our DNA. That is what we do in our funds such as Health for Life Capital™, and also in our portfolio companies”
adds Isabelle de Cremoux

Mycotechnology just inked a strategic partnership with one of the world-wide leaders in natural ingredients to promote and distribute its vegan protein Puretaste, which will be announced in the coming days.

-ENDS-

Notes to Editors

About Seventure Partners

With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies in France and Germany, and Life sciences across Europe, Israel and North America.

In Life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Recently, Seventure Partners successfully launched *Health for Life Capital™* which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis, as well as entrepreneurs and financial institutions.

For more details: <http://www.seventure.fr/en/> Twitter [@SeventureP](https://twitter.com/SeventureP)

About Health For Life Capital™

In 2013, Seventure Partners launched *Health for Life Capital™*, the first venture capital fund focused mainly on investments in the microbiome and nutrition space. Europe is the primary focus of the fund, but it also invests in North America, Israel and Asia. The €160m fund attracted strategic investments from prestigious organizations including Danone, Novartis, Tereos, Tornier, Lesaffre and Bel, as well as financial institutions and entrepreneurs. *Health for Life Capital™* is managed by Seventure’s Life sciences team.

For more details: <http://www.seventure.fr/en/>

Media contacts:		
<i>At the Company</i> Isabelle de Cremoux CEO and Managing Partner of Seventure Partners Tel: + 33 1 58 19 22 77 Email: isabelle.decremoux@seventure.fr	<i>In France</i> Agence Yucatan Caroline Prince-Albagnac Tel: +33 1 53 63 27 35 Email: cprince@yucatan.fr	<i>International</i> Instinctif Partners Sue Charles/ Gemma Harris Tel: +44 20 7866 7860 Email: seventure@instinctif.com

